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ABSTRACT
Nonmyeloablative allogeneic transplantation provides a valuable therapeutic option for patients with relapsed
non-Hodgkin lymphomas, particularly those that have recurred after autologous transplantation. However, the
absence of an intensive conditioning regimen renders this approach less effective for patients with aggressive
or bulky lymphoma because rapid tumor growth may outpace the evolution of the graft-versus-lymphoma
effect. Radioimmunotherapy provides an attractive, minimally toxic modality to safely prevent early progres-
sion of B-cell lymphomas and induce remissions without incurring the risks of traditional intensive therapy.
This approach provides a time window during which a robust graft-versus-lymphoma effect may be established
before tumor progression, thereby providing more effective long-term disease control. The rationale for
incorporation of radioimmunotherapy into reduced intensity allogeneic transplantation regimens for non-
Hodgkin lymphoma is discussed, as are current study designs, preliminary results, and future directions.
© 2006 American Society for Blood and Marrow Transplantation
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HNTRODUCTION
The curative potential of conventional allogeneic
ematopoietic cell transplantation (HCT) is due in
art to eradication of the malignant cell by high-dose
hemoradiation therapy and in part by immune-me-
iated graft-versus-tumor effects [1]. Unfortunately,
igh-dose myeloablative regimens are associated with
erious toxicities that have limited their use to
ounger, medically ﬁt patients despite the fact that the
ighest incidence of non-Hodgkin lymphoma (NHL)
ccurs in adults 60 years of age [2]. Nonmyeloabla-
ive allogeneic HCT has recently been introduced as a
ovel, potentially curative option for patients with
elapsed or refractory NHL that can overcome some
he limitations of traditional myeloablative therapies
3-8]. This approach is particularly attractive for pa-
ients who are not candidates for myeloablative autol- egous transplantation due to the inability to collect
utologous stem cells or the presence of excessive
omorbidities, or patients who are unable to undergo
raditional myeloablative allogeneic HCT as a result
f prior autologous transplantation, excessive comor-
idities, or advanced age. Allogeneic HCT also may
e more likely to cure patients with indolent lympho-
as than autologous transplantation, although the
outine application of this approach has been limited
y the high mortality rates of conventional myeloab-
ative allografting [9,10]. The attractiveness of nona-
lative allogeneic HCT emanates predominantly from
ts favorable toxicity proﬁle [3,11]. The reduced in-
ensity of the employed conditioning regimens mark-
dly attenuates early morbidity and mortality rates.
owever, this same attribute enhances the risk of
arly relapse because disease control is almost entirely
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A. K. Gopal et al.698eliant on the graft-versus-lymphoma effect, which
equires 30 to 60 days to develop [12]. This article
eviews the potential limitations of nonablative allo-
eneic HCT for NHL in terms of early disease con-
rol and summarizes the rationale and methods of
ncorporating radioimmunotherapy (RIT) into re-
uced intensity conditioning regimens.
UCCESS AND LIMITATIONS OF NONABLATIVE
LLOGENEIC HCT FOR NHL
Several centers have published pilot data regard-
ng the efﬁcacy of reduced intensity conditioning reg-
mens for NHL. Selected studies of nonablative alloge-
eic HCT for lymphoma are summarized in Table 1.
houri and colleagues [3] of the MD Anderson Cancer
enter published one of the earliest studies of non-
blative allogeneic HCT for indolent lymphoma, us-
ng a moderately intensive preparative regimen con-
isting of 5 days of ﬂudarabine with 1 g/m2 of
yclophosphamide. In this series of 20 patients with
elapsed or refractory lymphoma (predominantly fol-
icular lymphoma), 84% were estimated to be alive
nd without progression 2 years after HCT. However,
nly patients with chemosensitive disease were in-
luded in this trial; most had responded to cyclophos-
hamide and/or ﬂudarabine-based regimens, and 60%
ere in complete remission before transplantation.
In a second study, Maris and coworkers [4] eval-
ated the efﬁcacy of a low-intensity allogeneic condi-
ioning regimen consisting of 3 days of ﬂudarabine
ith 2-Gy total body irradiation in patients with re-
apsed or refractory mantle cell lymphoma. In this
eries of 33 patients, 42% had failed high-dose autol-
gous transplantation and 39% were refractory to
heir last therapy. Despite these features, 60% of pa-
ients were estimated to be alive and without progres-
ion after 2 years. A signiﬁcant association was ob-
erved between relapse and the receipt of 4 prior
egimens in this study (P  .01).
Morris and colleagues [6] formally evaluated the
isk factors for post-transplantation relapse in a mul-
able 1. Selected Trials of Nonablative Allogeneic HCT for Lymphoma
Study n Histology Chemosensi
houri et al [3] 20 FL/SLL 20 (
aris et al [4] 33 MCL 18 (
orror et al [5] 64 CLL/SLL 23 (
orris et al [6] 88 Various 78 (
orradini et al [7] 17 T-NHL 14 (
ean et al [8] 29 Various 12 (
obinson et al [13] 188 Various 133 (
FL indicates follicular lymphoma; SLL, small lymphocytic lymph
T-NHL, T-cell non-Hodgkin’s lymphoma; CR, complete remi
A partial or complete response to the most recent therapy beforeivariable analysis of 88 patients with NHL undergo- dng nonablative allogeneic HCT. Their ﬁndings sug-
ested that failure to achieve a complete remission
efore transplantation exerted the greatest adverse
ffect on the risk of relapse after transplantation (rel-
tive risk, 3.3; P  .0001) [6]. Concordant results
merged from a second series of 188 patients with
HL who were treated with nonablative allogeneic
CT, which identiﬁed response to chemotherapy as
he only signiﬁcant independent predictor of relapse,
ith 75% of patients with chemotherapy-resistant
ymphoma progressing within 1 year after transplan-
ation compared with 25% of patients with chemo-
herapy-sensitive disease (P .001) [13]. Unpublished
ata from our center that evaluated 64 patients with
hronic lymphocytic leukemia/small lymphocytic
ymphoma who underwent reduced intensity alloge-
eic HCT conﬁrmed these ﬁndings (Figure 1) and
emonstrated a 2-year relapse rate of 52% in patients
ith tumor masses 5 cm in diameter at time of
ransplantation compared with 14% for patients with
umors 5 cm (P  .009; Sorror et al, unpublished
ata). Together, these studies suggest that nonablative
llogeneic HCT has encouraging efﬁcacy for treat-
ent of NHL, but that results are inferior for patients
isease Status Before Transplantation*
(%) CR, n (%) >5 cm Bulk (%) PFS
12 (60) NA 84% at 2 y
13 (39) 6 (18) 60% at 2 y
5 (8) 18 (28) 52% at 2 y
21 (24) NA 30–49% at 3 y
2 (12) NA 64% at 3 y
3 (10) NA 32% at 3 y
49 (26) NA 46% at 1 y
CL, mantle cell lymphoma; CLL, chronic lymphocytic leukemia;
A, not available; PFS, profession-free survival.
antation.
igure 1. Effect of tumor bulk on the cumulative incidence of
elapse after nonablative allogeneic HCT for chronic lymphocytic
eukemia/small lymphocytic lymphoma (Sorror et al, unpublishedand D
tive†, n
100)
55)
36)
89)
82)
41)
71)
oma; M
ssion; Nata). LN indicates lymph node.
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RIT in Allogeneic Transplantation for NHL 699ith bulky, chemoresistant, or residual disease at time
f transplantation.
IT FOR TREATMENT OF NHL
RIT has recently emerged as one of the most
romising modalities for the treatment of NHL. Two
rugs have been approved by the US Food and Drug
dministration for treatment of relapsed or refractory
ollicular and transformed follicular NHL, namely
odine-131-tositumomab (Bexxar, GlaxoSmithKline,
hiladelphia, PA) and yttrium 90-ibritumomab-tiux-
tan (Zevalin, Biogen-Idec, Cambridge, MA). The
roperties and features of these agents are summa-
ized in Table 2. Objective response rates of 60% to
0% have been reported in multiple trials [14-17].
ore recently, data have suggested that RIT also is
ffective for treatment of more aggressive histologies
ncluding diffuse large B-cell lymphoma and mantle
ell lymphoma [18,19]. Because myelosuppression is
he major dose-limiting toxicity of RIT, HCT may be
he ideal setting for this modality. Furthermore, pa-
ients with NHL who undergo nonablative allogeneic
CT and are heavily pretreated with chemotherapy
ay be less cross-resistant to the use of radiation
herapy than to the use of additional chemotherapy.
ur group and others have used RIT at standard or
igh doses as part of a high-dose therapy regimen in
he setting of autologous transplantation and have
hown this approach to be feasible, efﬁcacious, and
afe, without a negative effect on engraftment [20-26].
hus, RIT may provide an optimal strategy for re-
uced intensity allogeneic transplantation condition-
ng by inducing an effective antitumor response with
inimal nonhematologic toxicity. This principle has
een validated by our group in the setting of alloge-
able 2. Properties of Food and Drug Administration Approved Radioi
nd Iodine-131-Tositumomab (Bexxar; GlaxoSmithKline)
Yttrium 90-Ibrit
ntibodies
Labeled antibody Ibritumomab t
Unlabeled antibody Rituximab (chi
arget CD20
sotopes
Therapeutic isotope Yttrium 90
Emission 
Beta energy 2.3 MeV
Pathlength 5 mm
Isotope halflife* 2.7 d
Imaging isotope Indium 111
Nonspecific uptake Bone, liver
Dose calculation‡ 0.4 mCi/kg (up
The in vivo biological half-time may be shorter due to clearance
Thyroid uptake can be blocked with oral Lugol solution or super
Dose reduction required for platelet counts 150 000/L.
The millicurie dose is variable based on individual dosimetry to deic HCT for acute leukemia, using CD45 targeted pIT, which has been shown to be feasible and effec-
ive in patients with relapsed acute myeloid leukemia
27-29].
PTIMIZING CONDITIONING REGIMENS
ONTAINING RIT
Johnson and Press [30] evaluated a variety of drugs
or their ability to synergize with iodine 131–based
nti-CD20 RIT in an in vitro lymphoma model to
eﬁne optimal combinations for transplantation con-
itioning regimens. These studies employed formal
sobolographic and dose modiﬁcation factor analyses
o demonstrate that nucleoside analogs such as cytar-
bine and ﬂudarabine synergize optimally with RIT,
hereas agents traditionally used in lymphoma trans-
lantation regimens such as cyclophosphamide and
toposide provided minimal synergy (Figure 2). Sub-
equent in vivo murine lymphoma xenograft studies
ave suggested that combinations of ﬂudarabine and
conjugates Yttrium-90-Ibritumomab-Tiuxetan (Zevalin; Biogen-Idec)
ab-Tiuxetan Iodine-131-Tositumomab
n (murine) Tositumomab (murine)
Tositumomab (murine)
CD20
Iodine 131
, 
0.6 MeV
1 mm
8 d
Iodine 131
Thyroid†
mCi) 75 cGy whole-body dose§
adioimmunoconjugate.
ted potassium iodide solution.
he desired whole-body radiation dose.
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igure 2. In vitro degree of synergy between iodine 131/anti-CD20
IT and chemotherapeutic agents (adapted from Johnson and Press
30]). Ara-C indicates cytarabine; Flu, ﬂudarabine; VP-16, etopo-
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A. K. Gopal et al.700odine 131 anti-CD20 antibodies improve survival of
ice bearing human lymphoma xenografts (Figure 3;
opal et al, unpublished data). These ﬁndings, in
oncert with knowledge of the effective T-cell abla-
ion provided by ﬂudarabine, has convinced our group
o combine RIT with concurrent ﬂudarabine as part of
he reduced intensity transplantation conditioning
egimen for lymphoma patients with substantial tu-
or bulk.
URRENT STUDIES OF RIT-BASED ALLOTRANSPLANTS
OR NHL
Our interest in developing a formal RIT-based
educed intensity transplantation protocol was height-
ned by early experiences of individual patients
reated with standard doses of Bexxar or Zevalin
hortly before undergoing standard nonablative allo-
eneic HCT. Encouraging outcomes in such patients
onvinced us to initiate formal studies using RIT as
art of reduced intensity allogeneic transplantation
onditioning at our center. The current study ap-
roved by the institutional review board uses yttrium-
0-ibritumomab tiuxetan at the standard dose (.4
Ci/kg) combined with ﬂudarabine (30 mg/m2  3
ays), total body irradiation (2 Gy on day 0), and
mmunosuppression with cyclosporine and mycophe-
olate mofetil starting on day 3 and day 0, respec-
ively (Figure 4). One notable deviation from our
raditional nonablative allogeneic HCT conditioning
egimen is that ﬂudarabine is administered on day 7
ather than on day 3 to overlap more extensively
ith RIT and provide a greater opportunity for syn-
rgy between these 2 agents [4]. This study permits
ccrual of patients who have received prior autologous
ransplants, have had prior dose limiting radiation,
nd have progressive, bulky, or chemoresistant disease
nd has safety as its primary endpoint. We anticipate
hat this trial will capture patients who have too great
disease burden for traditional reduced intensity al-
0
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igure 3. Overall survival of mice bearing human lymphoma xeno-
rafts treated with iodine-131-tositumomab (131I-anti-CD20), ﬂu-
arabine, iodine-131-tositumomab  ﬂudarabine, or diluent aloneLcontrol). (From Gopal et al, unpublished data.)ogeneic transplantation and those who are too old,
ave had too many prior therapies, or possess too
any signiﬁcant comorbidities to undergo traditional
yeloablative allogeneic transplantation. Six patients
ave provided written informed consent and been
nrolled in this ytttrium-90-ibritumomab–based allo-
eneic transplantation study to date. None of the
valuable patients have shown disease progression and
achieved an objective response by 1 month after
ransplantation, even though all patients had che-
oresistant lymphoma and a mean tumor bulk of 6.5
m at the time of study entry.
UTURE DIRECTIONS IN RIT-BASED
LLOTRANSPLANTS FOR NHL
We anticipate that standard RIT alone will not be
ufﬁcient to control lymphoma in all patients with
ery rapidly progressive or excessively bulky disease.
o overcome this clinical challenge, we anticipate that
uture studies will require escalation of the radiation
ose delivered to tumor sites. One approach is to
irror the regimens we have employed in our autol-
gous NHL transplantation and allogeneic acute my-
loid leukemia transplantation regimens by escalating
he dose of radiation delivered by RIT [20,21,27].
ther strategies include targeting radiation more se-
ectively to tumor sites using pretargeting methodol-
gies or extracorporeal immunoabsorption [31-34].
ased on these considerations, we anticipate that the
se of RIT will help overcome the limitations of
educed intensity allogeneic HCT in patients with
hemoresistant, bulky, or rapidly progressive lym-
hoid malignancies. We encourage continued devel-
pment and accrual to clinical trials so that the safety
nd efﬁcacy of these approaches can be most properly
valuated.
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